Reaction
Breast Cancer In Situ reporting signals
As of the last recalculation, Breast Cancer In Situ appears in 1,271 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE (PRR 310.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Conjugated Estrogens And Medroxyprogesterone Acetate | 331 | 310.2 | 314.6 |
| Medroxyprogesterone Acetate | 517 | 285.8 | 288.8 |
| Conjugated Estrogens | 492 | 224.9 | 226.8 |
| Estrogens, Conjugated | 494 | 222.3 | 224.1 |
| Raloxifene Hydrochloride | 34 | 39.2 | 39.2 |
| Estradiol | 155 | 33.3 | 33.4 |
| Progesterone | 33 | 24.2 | 24.3 |
| Estradiol Gel 0.1% | 48 | 18.0 | 18.1 |
| Estradiol Transdermal | 48 | 18.0 | 18.0 |
| Interferon Beta-1A | 101 | 9.2 | 9.2 |
| Teriparatide | 36 | 5.4 | 5.4 |
| Levonorgestrel | 40 | 3.3 | 3.3 |